Last reviewed · How we verify
NCT05313178: ABC
Changes in Plasma Amino Acid Appearance After Adding Bacillus Coagulans GBI-30, 6086 to Milk Protein Concentrate
NA trial testing Bacillus Coagulans GBI-30, 6086 in Protein Malabsorption in 30 participants. Completed in 1 February 2022.
1 February 2022
Quick facts
| Lead sponsor | Lindenwood University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | other |
| Enrollment | 30 |
| Start date | 20 November 2020 |
| Primary completion | 1 February 2022 |
| Estimated completion | 1 February 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Bacillus Coagulans GBI-30, 6086
Conditions studied
- Protein Malabsorption — all drugs for Protein Malabsorption →
Sponsor
Lindenwood University
Who can join
Adults 50 to 70, female only, with Protein Malabsorption. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to examine the pattern of plasma amino acid appearance after a two-week daily regimen of milk protein concentrate supplementation with and without the addition of Bacillus coagulans GBI-30, 6086 among older women.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Probiotic BC30 Improves Amino Acid Absorption from Plant Protein Concentrate in Older Women.
Walden KE, Hagele AM, Orr LS, Gross KN, et al · · 2024 · cited 13× · PMID 36515888 · DOI 10.1007/s12602-022-10028-4
Verify or expand the search:
- PubMed search for NCT05313178
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Protein Malabsorption
Currently open trials in the same condition.
- NCT06076187 — Protein Digestion After Bariatric Surgery in Older Adults · recruiting
Other Lindenwood University trials
Trials by the same sponsor.
- NCT07387991 — Evaluating the Ability of a Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms · NA · not yet recruiting
- NCT07388264 — Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes · NA · recruiting
- NCT07310108 — Evaluation of Cordyceps Militaris M2-116-04 for Its Potential Sport and Exercise Nutrition Applications in Healthy Activ · NA · completed
- NCT06672952 — Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Othe · NA · recruiting
- NCT07502924 — Dose-Response Impact of Geranylgeraniol (GG) Supplementation on Muscle Health · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05313178 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lindenwood University
- Last refreshed: 17 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05313178.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing